Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in GE HealthCare Technologies Inc. or Glaukos Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how GE HealthCare Technologies Inc. and Glaukos Corporation compare based on key financial metrics to determine which better meets your investment needs.

About GE HealthCare Technologies Inc. and Glaukos Corporation

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women’s health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women’s health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Latest Health Care Equipment & Supplies and GE HealthCare Technologies Inc., Glaukos Corporation Stock News

As of August 19, 2026, GE HealthCare Technologies Inc. had a $33.7 billion market capitalization, compared to the Health Care Equipment & Supplies median of $425.3 million. GE HealthCare Technologies Inc.’s stock is NA in 2026, NA in the previous five trading days and up 1.98% in the past year.

Currently, GE HealthCare Technologies Inc.’s price-earnings ratio is 17.2. GE HealthCare Technologies Inc.’s trailing 12-month revenue is $21.3 billion with a 9.3% net profit margin. Year-over-year quarterly sales growth most recently was 5.8%. Analysts expect adjusted earnings to reach $4.927 per share for the current fiscal year. GE HealthCare Technologies Inc. currently has a 0.2% dividend yield.

Currently, Glaukos Corporation does not have a price-earnings ratio. Glaukos Corporation’s trailing 12-month revenue is $612.8 million with a -30.7% net profit margin. Year-over-year quarterly sales growth most recently was 49.6%. Analysts expect adjusted earnings to reach $-0.291 per share for the current fiscal year. Glaukos Corporation does not currently pay a dividend.

How We Compare GE HealthCare Technologies Inc. and Glaukos Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at GE HealthCare Technologies Inc. and Glaukos Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

GE HealthCare Technologies Inc. and Glaukos Corporation’s Quality Grades

Company	Ticker	Quality
GE HealthCare Technologies Inc.	GEHC	B
Glaukos Corporation	GKOS	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

GE HealthCare Technologies Inc. has a Quality Score of 71, which is Strong. Glaukos Corporation has a Quality Score of 60, which is Average.

The Quality Grade Winner: GE HealthCare Technologies Inc.

As you can clearly see from the Quality Grade breakdown above, GE HealthCare Technologies Inc. has a better overall quality grade than Glaukos Corporation. For investors who are looking for companies with higher quality than others in the same industry, GE HealthCare Technologies Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

GE HealthCare Technologies Inc. and Glaukos Corporation’s Momentum Grades

Company	Ticker	Momentum
GE HealthCare Technologies Inc.	GEHC	C
Glaukos Corporation	GKOS	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

GE HealthCare Technologies Inc. has a Momentum Score of 52, which is Average. Glaukos Corporation has a Momentum Score of 90, which is Very Strong.

The Momentum Grade Winner: Glaukos Corporation

As you can clearly see from the Momentum Grade breakdown above, Glaukos Corporation is considered to have stronger momentum compared to GE HealthCare Technologies Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Glaukos Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

GE HealthCare Technologies Inc. and Glaukos Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
GE HealthCare Technologies Inc.	GEHC	C
Glaukos Corporation	GKOS	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

GE HealthCare Technologies Inc. has a Earnings Estimate Score of 51, which is Neutral. Glaukos Corporation has a Earnings Estimate Score of 73, which is Positive.

The Earnings Estimate Revisions Grade Winner: Glaukos Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Glaukos Corporation has a better Earnings Estimate Revisions Grade than GE HealthCare Technologies Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Glaukos Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other GE HealthCare Technologies Inc. and Glaukos Corporation Grades

In addition to Momentum, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether GE HealthCare Technologies Inc. and Glaukos Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, GE HealthCare Technologies Inc. or Glaukos Corporation Stock?

Overall, GE HealthCare Technologies Inc. stock has a Momentum Score of 52, Estimate Revisions Score of 51 and Quality Score of 71.

Glaukos Corporation stock has a Momentum Score of 90, Estimate Revisions Score of 73 and Quality Score of 60.

Comparing GE HealthCare Technologies Inc. and Glaukos Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.